Milestones
Beginning in 1993, 3SBio dares to innovate and pursues excellence. After 20 years of rapid development, 3SBio Group has now become a leading Chinese biopharmaceutical company that integrates R&D, production and sales, and has achieved great success in the international market.
-
1993
Shenyang Sunshine Pharmaceuticals Co., Ltd. was established.
In 1993, Shenyang Sunshine Pharmaceuticals CO., Ltd was founded by the 58-year-old Major General Lou Dan and his team. Lou Dan is a member of the National Medical Review Committee, a well-known bioengineering medical expert and the previous director of the Institute of Microbiology and Immunology of Shenhou Military Medical Research Institute and served as the chairman and president as well as chief engineer of the company.
-
1995
In 1995, Intefen (recombinant human interferon α2a injection) was launched. In 2000, Mr Lou Dan, founder of the company, first proposed that “To make the Interferon as affordable as penicillin for ordinary people”, whipping up price reduction storm in the bio-pharmaceutical industries
In April 1995, Intefen was approved to be manufactured by NMPA.
In December 1995, Intefen was launched and is included in the National Medical Insurance Catalogue as a Category B drug. -
1996
Inleusin (recombinant human interleukin-2 for injection) was listed
In June 1995, NMPA production approval documents were obtained for Inleusin.
This product was launched in March 1996 and is included in the National Medical Insurance Catalogue as a Category B drug.
-
1998
EPIAO (recombinant human erythropoietin injection (CHO cell)) was listed, which was one of the first rhEPO products marketed in China. Since 2002, it has been the leading brand of China’s erythropoin market
In 1998, EPIAO was marketed with approval of the NMPA, which was the first rhEPO products marketed in China. Since 2002, it has been the leading brand of China’s erythropoin market. It is included in the National Medical Insurance Catalogue as a Category B drug.
-
2002
In 2002, SEPO (recombinant human erythropoietin injection (CHO cell)) and SPARIN (injectable low-molecular-weight heparin calcium) were listed and included in the product team of the Group in 2014
NMPA production approval documents were obtained for SEPO in 2001.It was listed in 2002 and is included in the National Medical Insurance Catalogue as a Category B drug. In 2014, SEPO was rated as famous trademark by Guangdong Province Administration for Industry & Commerce. SPARIN was approved by the NMPA and listed in 2002.
-
2005
Co-founder Dr. Lou Jing led the research and development of TPIAO as a new class of Chinese medicine (recombinant human thrombopoietin injection), which was listed and the only commercial platelet-derived growth factor in the world
In 2005, TPIAO was listed and has been approved by the NMPA for two indications that are the treatment of chemotherapy-induced thrombopenia (approved in 2005) and immune thrombocytopenia (ITP) (approved in 2010), which is included in the National Medical Insurance Catalogue as a Category B drug of western medicine.
The first antibody fusion protein in China, YISAIPU (recombinant human tumor necrosis factor-α receptor Ⅱ: IgG-Fc fusion protein for injection) was listed, and was included in the product team of the Group in 2016
YISAIPU was marketed in 2005 and is the first antibody fusion protein medicine marketed in the rheumatism field of China. 2 kinds of indications were approved by the NMPA: Treatment of rheumatoid arthritis (approved in 2005), ankylosing spondylitis and psoriasis (approved in 2007). It is included in the National Medical Insurance Catalogue as a Category B drug of western medicine.
-
2006
Through Sunshine (Liaoning), we obtained the exclusive right to the distribution of iron sucrose injection.
-
2007
It is listed on NASDAQ
-
2009
Qiming granule (National protected traditional Chinese medicines) was listed for treatment of type II diabetic retinopathy simplex and was included in the product team of the Group in 2015
Qiming granule is an exclusive formula of TCM, indicated for the treatment of Type 2 diabetic retinopathy.
It is the project achievement of Science and Technology Development during the “9th Five-Year Plan” and “10th Five-Year Plan” and support plan during the “11th Five-Year Plan” and was identified as a national protected traditional Chinese medicine by NMPA in 2013. Qiming granule is the first NMPA-approved new Chinese medicine for treatment of diabetic retinopathy and is included in the National Medical Insurance Catalogue as a Category B drug of Chinese patent medicine.
-
2010
We completed the construction of additional production facilities for EPIAO and TPIAO in Shenyang Economic and Technological Development Zone.
These facilities have been certified by NMPA and comply with the major international regulatory guidelines (including regulations of the cooperation plan between European Food and Drug Administration and International Drug Inspection).These facilities have increased the production capacity of EPIAO and TPIAO by approximately four times.
-
2011
NMPA approved that we voluntarily upgrade product quality manufacturing standards of EPIAO to full compliance with European Pharmacopoeia standards.
-
2013
The company was privatized by the buyer group led by management and CITIC PE, and was delisted from NASDAQ.
-
2014
we acquired the Sciprogen Bio-pharmaceutical Co.,Ltd. based in China.
We also acquired Sirton, a contract drug manufacturer based in Italy.
We separately entered into a strategic cooperation agreement with CPGJ, and acquired approximately 6.96% of stock rights from CPGJ.
-
2015
3SBio was successfully listed on the Main Board of the Hong Kong Stock Exchange; and acquired and integrated Zhejiang Wansheng Pharmaceutical Co., Ltd. (later renamed 3SBio Mandi).
-
2016
Acquired and integrated CITIC Guojian (later renamed Sunshine Guojian) to strengthen the antibody drug platform; and established a high-end CDMO service platform — 3SBio Guangdong — in Dongguan, Guangdong.
-
2017
TPIAO®, Yisaipu®, and Qiming Granules were included in the 2017 NRDL;
Shinuo® (Fluticasone Propionate Cream) was launched.
-
2019
Xenopax® (Recombinant Humanized Anti-CD25 Monoclonal Antibody Injection), independently developed by Sunshine Guojian, a controlling subsidiary of 3SBio Group, received a GMP certificate from the National Medical Products Administration (NMPA) of China. The product is indicated for the prophylaxis of acute rejection following renal transplantation.
-
2020
Sunshine Guojian was successfully listed on the Shanghai Stock Exchange STAR Market (stock code: 688336.SH);
Cipterbin® Inetetamab for Injection was approved for marketing and included in the NRDL as a negotiated drug within the agreement period. As China’s first domestically developed innovative anti-HER2 monoclonal antibody indicated for HER2-positive metastatic breast cancer, it was selected for the National Major Science and Technology Project for “Significant New Drug Development” and received recognition as one of the Shanghai Key Science and Technology Research Projects and as one of the Top 100 Shanghai High-Tech Achievement Transformation Projects. In the same year, Saiboning® (Nadroparin Calcium Injection) was launched.
-
2021
In December 2021, 3SBio established its CDMO platform, Shanghai SIGO Biologics Ltd. (SIGO), to fully expand its CDMO services. Backed by proprietary culture media and chromatography resins, SIGO supports the development and manufacturing of monoclonal, bispecific, and multispecific antibodies as well as other complex modalities.
-
2023
The prefilled syringe formulation of Yisaipu® (Recombinant Human Tumor Necrosis Factor Receptor Type II-IgG Fc Fusion Protein) was approved for marketing;
Remitch® (Nalfurafine Hydrochloride Orally Disintegrating Tablets) was approved for marketing. Originally developed by Toray Industries, Japan, it is China’s first NRDL-listed negotiated originator drug approved for hemodialysis-associated pruritus. It is recommended by multiple Chinese, European, and Japanese guidelines and consensus statements as a treatment for CKD-aP;
Phase I of Desheng Biotech was completed, with a bioreactor capacity of 72,000 liters;
3SBio Guangdong obtained the pharmaceutical manufacturing license.
-
2024
Stage A of the Desheng Biotech Phase II project was completed;
Mandi® Minoxidil Foam was launched, marking China's first and currently only domestically developed minoxidil foam formulation approved for marketing.
Liporaxel® (Paclitaxel Oral Solution) was launched, marking the world's first and only oral paclitaxel formulation approved for marketing; Teaisheng® (Eltrombopag Ethanolamine Powder for Oral Suspension) was launched, marking the only eltrombopag ethanolamine powder for oral suspension available on the Chinese market;
Apremilast Tablets were launched.
-
2025
Granted Pfizer global development and commercialization rights to SSGJ-707, a PD-1/VEGF bispecific antibody, with the upfront payment setting a record for out-licensing deals of China-originated innovative drugs and the total transaction value exceeding US$6 billion.
-
2026
Three internally developed Class 1 innovative biologics were approved for marketing——Yisaituo®(amdokitug injection), NuPIAO® (loncipetin alfa injection)® and Yisaina® (anflekitug injection)®
